Sunesis Pharmaceuticals, Inc.

Merck Sharp + Dohme Corp.

Bruce Fahr

Craig Alan Coburn

Melissa S Egbertson

Wenjin Yang

Shaun R Stauffer

Georgia B McGaughey

Wanli Lu

Harold G Selnick

Samuel L Graham

Kenneth Jay Barr

James C Barrow

Johan D Oslob

Shawn J Stachel

Philippe G Nantermet

Christian Wiesmann

Hemaka Anthony Rajapakse

Brian Raimundo

Lou Anne Neilson

Zhi-Qiang Yang

Kenneth E Rittle

Melody McWherter

Stig Hansen

Michael J Romanowski

Darin Allen

Hemaka A Rajapakse

Georgia B Mcgaughey

Melody A Mcwherter

Shawn R Stachel

The present invention is directed to spiropiperidine compounds of formula (I) and tautomers thereof, which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease

The present invention is directed to spiropiperidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease

The invention provides compounds of Formula I and derivatives thereof, pharmaceutical compositions comprising a compound of Formula I, and methods of treatment utilizing such compounds and compositions:  

Caspase-1 inhibitors and methods for their use

The present invention relates to a new and improved method for treating diabetes and or its associated complications by modulating the activity of protein tryosin phosphatase 1B (&ldquo;PTP-1B&rdquo;). The inventive compounds modulate the activity PTP-1B by binding to a novel binding site referred herein as the PTP-1B exosite that is distal to the active site of PTP-1B. The present invention also relates to a new and improved method of treating immune system disorders by modulating the activity of T-cell protein tyrosine phosphatase (&ldquo;TC-PTP&rdquo;). The inventive compound modulate the activity of TC-PTP by binding to a novel binding site referred herein as the TC-PTP exosite that is distal to the active site of PTP-1B.

Compounds that modulate the activity of PTP-1B and TC-PTP

Growing community of inventors

Foster City, CA, United States of America

Bruce Fahr